BFRI
What one share of Biofrontera holds
Pharmaceutical Preparations
Biofrontera’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $3.92 |
|---|---|
| Profit | −$0.54 |
| Capex (buildings and equipment) | $0.00 |
| Free cash flow | −$0.67 |
| Cash and investments | $0.33 |
| Book value | $0.42 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2022 | $27.13 | −$0.61 | $0.04 | −$15.36 | — | $17.89 |
| 2023 | $22.03 | −$13.02 | $0.00 | −$16.10 | — | $3.16 |
| 2024 | $6.77 | −$3.22 | $0.00 | −$1.86 | — | $0.50 |
| 2025 | $4.10 | −$1.04 | $0.00 | −$1.31 | — | $0.90 |